On October 22, 2026, the day after Getinge AB released its third-quarter report, several financial institutions raised their price targets for the medical technology company. The institutions were Nordea, SB1, SEB, Danske Bank and DNB Carnegie. Handelsbanken upgraded its recommendation on the stock to buy.
Analysts reportedly cited improved margins and expected savings from lower quality-related costs in the coming years. Getinge’s Q3 report showed higher profitability and strong cash flow, and adjusted EBITA exceeded consensus expectations.